Navigation Links
Revolutionary Healing Technology for Treating Difficult and Chronic Wounds Approved by Health Canada
Date:6/6/2008

TORONTO, June 6 /PRNewswire/ - Archimed, the woundcare division of Insense Ltd., today announced it has received approval from Health Canada for the use of its revolutionary Oxyzyme product in the treatment of difficult and chronic wounds. Oxyzyme was first trialed in Toronto by Dr. Gary Sibbald, one of the world's leading wound care specialists, in 2004 by his team at the Toronto Wound Healing Centres. The announcement was made at the 3rd Congress of the World Union of Wound Healing Societies taking place from June 4-8, 2008 at the Metro Toronto Convention Center.

Oxyzyme is a biochemical system in a dressing that ensures the oxygen in the wound environment meets the diverse oxygen needs of the cells responsible for healing. Ongoing clinical programs being undertaken in Europe are showing that 20% of old, previously unhealable wounds (3.5 years) are now closing in six weeks or under when dressed with Oxyzyme. Easy to use by any clinical professional, Oxyzyme will now soon be available to the Canadian health care system at a modest cost.

In conjunction with the announcement, Professor T.K. Hunt, often cited as the father of modern wound care, was awarded a lifetime achievement award by the World Union of Wound Healing Societies. Professor Hunt's insight and discoveries on the role oxygen plays in the healing process was the inspiration behind the development of Oxyzyme.

"The real value of Oxyzyme is that it combines two agents - iodine and oxygen - that are essential to the process of wound healing and provides further opportunities to overcome barriers to healing that may exist in the patient," explained Dr. Keith Harding, leading figure in the international wound care community and also a member of the World Union faculty.
For more information about Oxyzyme and Archimed visit http://www.archimed.co.uk.

About Insense Ltd.

------------------ Insense is a British biotechnology company founded by Professor Paul Davis, Chief Scientific Officer, who led the team which invented and developed the ClearBlue(TM) pregnancy test. The company is also developing products out of its core technology for dermatology and health and beauty applications. For more information about Insense Ltd. visit http://www.insense.co.uk.


'/>"/>
SOURCE Insense Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ORF Genetics Opens Revolutionary Green Factory in Iceland
2. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
3. SimBioSys Utilizes Revolutionary Hardware Technology to Open New Frontiers in Molecular Modeling
4. NASA MidSTAR-1 successful technologies may be revolutionary
5. NEXCORE Technology Obtains Licenses for Revolutionary Fluid Management System
6. Webcam MD - Launch of revolutionary web-based medical technology
7. FDA Clears Biospace meds Revolutionary Low Dose Xray Imager
8. Cooler Solutions and Leading Research Hospital to Design Revolutionary Osteoporosis Diagnosis Device
9. Cardicas C-Port(R) Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed-Chest Heart Bypass Surgeries
10. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
11. Advanced BioHealing and Regenesis Biomedical Form Co-Promotion Alliance for Dermagraft(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... ... February 17, 2017 , ... ... (ASBMT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) will ... Fla. , The combined scientific sessions offer investigators, clinicians, laboratory technicians, ...
(Date:2/17/2017)... Mass. , Feb. 17, 2017  If ... small tumor had a mutation-conferring resistance to chemotherapy, ... Recently, genomics research has focused on finding these ... or even from circulating tumor DNA in blood ... new oncology therapeutics. Unfortunately, however, detecting ...
(Date:2/16/2017)... PHILADELPHIA , Feb. 16, 2017  ImMAGE Biotherapeutics (OTCMKTS: ... immune system to find a better treatment for triple negative ... Start in France program. ... is an accelerator designed to help entrepreneurs grow their business ... was one of eight American companies selected to complete an ...
(Date:2/16/2017)... , Feb. 16, 2017   Capricor Therapeutics, ... clinical-stage biotechnology company developing first-in-class biological therapies for ... it has elected to terminate its license agreement ... receptor agonists, including Cenderitide. "Our decision ... as we prioritize our efforts to advance our ...
Breaking Biology Technology:
(Date:1/30/2017)... , Jan. 30, 2017   Invitae Corporation ... fastest growing genetic information companies, today announced that it ... results and provide 2017 guidance on Monday, February 13, ... call that day at 4:45 p.m. Eastern / 1:45 ... management team will briefly review financial results, guidance, and ...
(Date:1/24/2017)... , Jan. 24, 2017  It sounds simple ... sock that monitors vital signs and alerts parents ... infant,s oxygen saturation level drops. But pediatric experts ... to parents, with no evidence of medical benefits, ... are marketed aggressively to parents of healthy babies, ...
(Date:1/18/2017)... , Jan. 18, 2017  In vitro diagnostic ... to mergers and acquisitions (M&A), and Kalorama Information expects ... such acquisitions have been shifting. Generally, uncertainty in reimbursement ... and the U.S. has changed the acquisitions landscape. Instead ... resulted in companies buying partners outside of their home ...
Breaking Biology News(10 mins):